Exchange: NYSE·Updated 11:23 AM EDT

NVO News

News
all
press releases
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.read more...
Benzinga
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.read more...
Benzinga
More News
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen its metabolic disease ambitions.
Zacks
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
Stocktwits
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum
Walmart, Visa and Novo Nordisk headline Zacks' latest analyst reports, with digital growth, rising competition and earnings pressures shaping their outlooks.
Zacks
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira...
Nasdaq News: Markets
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.
Zacks
Top Analyst Reports for Walmart, Visa & Novo Nordisk
Walmart, Visa and Novo Nordisk headline today's analyst reports, with digital growth, payment innovation and obesity-drug demand offset by rising costs and competition.
Zacks
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Zacks
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations pose challenges.
Zacks
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsBristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation...
Nasdaq News: Markets

Advertisement|Remove ads.